company background image
813 logo

Dezhan Healthcare SZSE:000813 Stock Report

Last Price

CN¥2.29

Market Cap

CN¥5.0b

7D

-0.9%

1Y

-24.4%

Updated

14 Jun, 2024

Data

Company Financials

Dezhan Healthcare Company Limited

SZSE:000813 Stock Report

Market Cap: CN¥5.0b

813 Stock Overview

Engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People’s Republic of China.

813 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health4/6
Dividends0/6

Dezhan Healthcare Company Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Dezhan Healthcare
Historical stock prices
Current Share PriceCN¥2.29
52 Week HighCN¥4.70
52 Week LowCN¥2.18
Beta0.33
1 Month Change-15.81%
3 Month Change-21.31%
1 Year Change-24.42%
3 Year Change-49.11%
5 Year Change-70.94%
Change since IPO-76.73%

Recent News & Updates

We Like The Quality Of Dezhan Healthcare's (SZSE:000813) Earnings

Apr 18
We Like The Quality Of Dezhan Healthcare's (SZSE:000813) Earnings

Recent updates

We Like The Quality Of Dezhan Healthcare's (SZSE:000813) Earnings

Apr 18
We Like The Quality Of Dezhan Healthcare's (SZSE:000813) Earnings

Shareholder Returns

813CN PharmaceuticalsCN Market
7D-0.9%-0.7%-0.07%
1Y-24.4%-11.9%-15.5%

Return vs Industry: 000813 underperformed the CN Pharmaceuticals industry which returned -11.9% over the past year.

Return vs Market: 000813 underperformed the CN Market which returned -15.5% over the past year.

Price Volatility

Is 813's price volatile compared to industry and market?
813 volatility
813 Average Weekly Movement5.6%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement6.7%
10% most volatile stocks in CN Market10.2%
10% least volatile stocks in CN Market4.1%

Stable Share Price: 000813's share price has been volatile over the past 3 months.

Volatility Over Time: 000813's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19801,002Wei Liuwww.dezhanhealthcare.com

Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People’s Republic of China. The company’s products include Vastatin Calcium Tablets (Nile), Trimetazidine Hydrochloride capsules, Fanle type I and II tablets, Azathioprine tablets, Amiodarone Hydrochloride tablets, Hydroxyurea tablets, Colchicine tablets, etc. It also offers biological peptide products, food and beverages, cosmetics, and other products. The company was founded in 1980 and is based in Beijing, the People’s Republic of China.

Dezhan Healthcare Company Limited Fundamentals Summary

How do Dezhan Healthcare's earnings and revenue compare to its market cap?
813 fundamental statistics
Market capCN¥4.96b
Earnings (TTM)CN¥64.65m
Revenue (TTM)CN¥464.18m

76.7x

P/E Ratio

10.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
813 income statement (TTM)
RevenueCN¥464.18m
Cost of RevenueCN¥213.94m
Gross ProfitCN¥250.24m
Other ExpensesCN¥185.59m
EarningsCN¥64.65m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.03
Gross Margin53.91%
Net Profit Margin13.93%
Debt/Equity Ratio0.01%

How did 813 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.